AB8054

Anti-ErbB2 / HER2 抗体 [CB11]

Name: Anti-ErbB2 / HER2 抗体 [CB11] (ab8054) | Abcam
Brand: Abcam Limited
SKU: AB8054
Price: 75000 JPY
Availability: InStock

Anti-ErbB2 / HER2 antibody [CB11]

Be the first to review this product! Submit a review

(34 Publications)

Mouse Monoclonal ErbB2 / HER2 antibody. Suitable for IHC-P and reacts with Human samples. Cited in 34 publications. Immunogen corresponding to Synthetic Peptide within Human ERBB2.

別名を表示する

CD340, HER2, MLN19, NEU, NGL, ERBB2, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, MLN 19

1 Images

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ErbB2 / HER2 antibody [CB11] (AB8054)

IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ErbB2 / HER2 antibody [CB11] (AB8054)

ab8054 labelling ErbB2 / HER2 in human breast; invasive ductal carcinoma.

Key facts

宿主種

Mouse

クローン性

Monoclonal

クローン番号

CB11

アイソタイプ

IgG1

軽鎖のタイプ

unknown

キャリアフリー

交差種

Human

アプリケーション

IHC-P

applications

免疫原

Synthetic Peptide within Human ERBB2. The exact immunogen used to generate this antibody is proprietary information.

P04626

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>" } } }

style

left-column

製品の詳細

C-erbB-2 oncogene codes for a membrane protein, Neu protein. In several studies the amplification of C-erbB-2 oncogene in carcinomas has been reported. Overexpression of the Neu oncogene protein can be demonstrated by this antibody.

style

left-column

出荷温度及び保存条件

製品の状態

Liquid

精製度

Tissue culture supernatant

バッファー組成

pH: 7.3 Preservative: 0.1% Sodium azide

出荷温度

Blue Ice

短期保存期間

1-2 weeks

短期保存温度

+4°C

長期保存温度

-20°C

分注に関する情報

Upon delivery aliquot

保管に関する情報

Avoid freeze / thaw cycle

style

left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

The ErbB2 also known as HER2 or HER2 protein is a transmembrane receptor protein with a molecular weight of about 185 kDa. It serves as part of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. The ErbB2 protein is expressed mainly in epithelial tissues including those of the breast and the gastrointestinal tract. It lacks a known ligand-binding domain which sets it apart from other members of its family. Due to its structure ErbB2 dimerizes with other members of the EGFR family to exert its effects in cellular signaling.

Biological function summary

The role of ErbB2 extends beyond a singular function. It becomes an active component when forming heterodimers with other EGFR family members such as ErbB3 to initiate various downstream signaling cascades. The dimerization activates intracellular pathways leading to cell proliferation survival differentiation and migration. Within cells ErbB2 influences processes critical for normal development and tissue homeostasis contributing significantly to signal transduction networks.

Pathways

ErbB2 plays a pivotal role in pathways such as the PI3K/Akt and MAPK/ERK pathways. These pathways are important in mediating cellular responses to growth signals. The PI3K/Akt pathway activated by HER2 signaling regulates cell growth and survival while the MAPK/ERK pathway contributes to cell differentiation and proliferation. ErbB2's interaction with proteins like ErbB3 is fundamental in these pathways increasing the amplitude and diversity of downstream signals.

ErbB2 is significantly associated with breast cancer and gastric cancer. The overexpression or gene amplification of HER2 is observed in approximately 20% of breast cancer cases correlating with aggressive tumor growth and poor prognosis. ErbB2-related signaling contributes to oncogenic processes by promoting excessive cell proliferation. Targeting ErbB2 in these cancers is common using therapies such as monoclonal antibodies like trastuzumab. In the context of gastric cancer the role of ErbB2 mirrors its function in breast cancer and targeting HER2 holds therapeutic potential.

style

left-column

style

left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

ターゲットの情報

The protein expressed by the ERBB2 gene is a protein tyrosine kinase involved in several cell surface receptor complexes, requiring a coreceptor for ligand binding. It is an essential component of a neuregulin-receptor complex, although neuregulins do not bind to it directly. GP30 is a potential ligand for this receptor. ERBB2 regulates the outgrowth and stabilization of peripheral microtubules (MTs) via the MEMO1-RHOA-DIAPH1 signaling pathway, which, upon activation, phosphorylates and inhibits GSK3B at the cell membrane. This prevents APC and CLASP2 phosphorylation, allowing their association with the cell membrane, facilitating MACF1 localization necessary for microtubule capture and stabilization. In the nucleus, ERBB2 is involved in transcriptional regulation, associating with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter to activate transcription. It is implicated in the transcriptional activation of CDKN1A, involving STAT3 and SRC, and participates in the transcription of rRNA genes by RNA Pol I, thereby enhancing protein synthesis and cell growth. This supplementary information is collated from multiple sources and compiled automatically.

See full target information ERBB2

style

left-column

文献 (34)

Recent publications for all applications. Explore the full list and refine your search

Molecular cancer therapeutics : PubMed40911899

2025

Anti-tumor activity of trastuzumab deruxtecan in pediatric solid tumors with variable HER2 expression.

Applications

Unspecified application

Species

Unspecified reactive species

Chelsey M Burke,Tamar Y Feinberg,Samantha Brosius,Umeshkumar K Bhanot,Mala Jain,Irina Linkov,Armaan Siddiquee,Kristina Guillan,Glorymar Ibanez,Andoyo A Ndengu,Paul Calder,Nestor Rosales,Diego F Coutinho,Matthew M Long,Raina Fishkin,Sheeno Thyparambil,Julia L Glade Bender,Damon R Reed,Daoqi You,Michael V Ortiz,Emily K Slotkin,Andrew L Kung,Filemon S Dela Cruz

Balkan medical journal 42:150-156 PubMed40033677

2025

Upregulation of miR-99b-5p Modulates ESR1 Expression as an Adaptive Mechanism to Circumvent Drug Response via Facilitating ER/HER2 Crosstalk.

Applications

Unspecified application

Species

Unspecified reactive species

Senem Noyan,Bala Gür Dedeoğlu

Turkish journal of biology = Turk biyoloji dergisi 48:153-162 PubMed39051060

2024

miR-770-5p-induced cellular switch to sensitize trastuzumab resistant breast cancer cells targeting HER2/EGFR/IGF1R bidirectional crosstalk.

Applications

Unspecified application

Species

Unspecified reactive species

Senem Noyan,Bala Gür Dedeoğlu

Asian Pacific journal of cancer prevention : APJCP 25:2193-2201 PubMed38918683

2024

Evaluation of the Expression EGFR, HER2/NEU and the End Effector ERK of the RAS/RAF/MAP Kinase Pathway in Prostatic Adenocarcinoma for a Possible Role as New Target Therapy.

Applications

Unspecified application

Species

Unspecified reactive species

Asem Shalaby,Heba A Mahmoud,Shayma G Sayed,Khalid Al Hashmi,Shadia Al-Sinawi,Suad Al Badi,Afrah Al Rashdi,Samya Al Husaini,Hajer Al Badi,Somaia Ahmed Saad El-Din

Nature cancer 5:880-894 PubMed38658775

2024

Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial.

Applications

Unspecified application

Species

Unspecified reactive species

Meenakshi Hegde,Shoba Navai,Christopher DeRenzo,Sujith K Joseph,Khaled Sanber,Mengfen Wu,Ahmed Z Gad,Katherine A Janeway,Matthew Campbell,Dolores Mullikin,Zeid Nawas,Catherine Robertson,Pretty R Mathew,Huimin Zhang,Birju Mehta,Raksha R Bhat,Angela Major,Ankita Shree,Claudia Gerken,Mamta Kalra,Rikhia Chakraborty,Sachin G Thakkar,Olga Dakhova,Vita S Salsman,Bambi Grilley,Natalia Lapteva,Adrian Gee,Gianpietro Dotti,Riyue Bao,Ahmed Hamed Salem,Tao Wang,Malcolm K Brenner,Helen E Heslop,Winfried S Wels,M John Hicks,Stephen Gottschalk,Nabil Ahmed

Journal of cellular and molecular medicine 27:2424-2436 PubMed37386793

2023

Contribution of PGAP3 co-amplified and co-overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Dong Wang,Siyu Hao,Hongjie He,Jian Zhang,Ge You,Xin Wu,Rui Zhang,Xiangning Meng,Xiaobo Cui,Jing Bai,Songbin Fu,Jingcui Yu

Turkish journal of biology = Turk biyoloji dergisi 47:199-207 PubMed37529418

2023

miR-216b-5p promotes late apoptosis/necroptosis in trastuzumab-resistant SK-BR-3 cells.

Applications

Unspecified application

Species

Unspecified reactive species

İştar Burcu Dolapçi,Senem Noyan,Ayşegül Yücel Polat,Hakan Gürdal,Bala Gür Dedeoğlu

Cancers 13: PubMed33919468

2021

HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models.

Applications

Unspecified application

Species

Unspecified reactive species

Andreia Gameiro,Catarina Nascimento,Jorge Correia,Fernando Ferreira

Frontiers in oncology 11:608201 PubMed33842315

2021

Discovery and Pharmacological Evaluation of STEAP4 as a Novel Target for HER2 Overexpressing Breast Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Ioanna-Maria Orfanou,Orestis Argyros,Andreas Papapetropoulos,Sofia Tseleni-Balafouta,Konstantinos Vougas,Constantin Tamvakopoulos

Head & neck 43:1983-1994 PubMed33660372

2021

Human epidermal growth factor receptor 2 expression in head and neck squamous cell carcinoma: Variation within and across primary tumor sites, and implications for antigen-specific immunotherapy.

Applications

Unspecified application

Species

Unspecified reactive species

Emilie A K Warren,Joshua Anil,Patricia D Castro,Jan Kemnade,Masataka Suzuki,Meenakshi Hegde,John Hicks,Wendong Yu,Vlad Sandulache,Andrew G Sikora

View all publications

style

left-column

style

left-column

style

right-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。

保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-ErbB2 / HER2 抗体 [CB11]

Anti-ErbB2 / HER2 antibody [CB11]

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ErbB2 / HER2 antibody [CB11] (AB8054)

Key facts

宿主種

クローン性

クローン番号

アイソタイプ

軽鎖のタイプ

キャリアフリー

交差種

アプリケーション

免疫原

Reactivity data

製品の詳細

出荷温度及び保存条件

製品の状態

精製度

バッファー組成

出荷温度

短期保存期間

短期保存温度

長期保存温度

分注に関する情報

保管に関する情報

補足情報

Biological function summary

Pathways

製品プロトコール

ターゲットの情報

文献 (34)

代替製品

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

組合せ製品

Assay Kits

Primary Antibodies

Secondary Antibodies

Primary Antibodies

Primary Antibodies

Abcam product promise